Drug Profile
Research programme: growth hormone antagonists - Asterion/Ipsen
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ipsen
- Class Recombinant fusion proteins
- Mechanism of Action Somatotropin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acromegaly
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acromegaly in Europe (Parenteral)
- 05 Feb 2009 Preclinical development is ongoing in Europe
- 30 Jan 2007 Preclinical trials in Acromegaly in Europe (Parenteral)